AI assistant
4SC AG — Share Issue/Capital Change 2007
Sep 7, 2007
5_rns_2007-09-07_d2d9b034-012d-4a0e-b7e5-4a37d7960155.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
News Details
Ad-hoc | 7 September 2007 17:06
4SC AG: Capital Increase and Placement of new 4SC AG Shares
4SC AG / Capital Increase
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
Planegg-Martinsried, Germany, 07 September 2007 - The Martinsried-based
drug discovery and development company 4SC AG (Frankfurt, Prime Standard:
VSC) announces the placement of new shares, after the Management Board,
with the approval of the Supervisory Board, passed a resolution to
authorise an increase of share capital on 20 August 2007. By means of this
decision on capital increase the company responded to the substantial
demand of an investor. The capital increase from the authorised capital
included a collateral rights offering to existing shareholders at a
subscription price of 2.65 Euro per share. The remaining unsubscribed
shares were completely used for a private placement at the subscription
price. The capital increase generated approx. 16.78 million Euros in gross
proceeds for the company. The company will use the proceeds for the further
development of the existing project pipeline, and to add new projects.
Following the completion of the capital increase, a total of 6,333,942 new
shares were placed. As a result of the capital increase, 4SC AG’s
subscribed capital increased to 19,001,826.00 Euros, and the free float to
27.79 percent of issued shares. The approval of the new shares for trading
at the Frankfurt Stock Exchange is not expected before week 42.
The capital increase was accompanied by Conrad Hinrich Donner Bank AG.
Information and Explaination of the Issuer to this News:
The establishment of a comprehensive, effective pipeline with drug
candidates that are attractive for the pharmaceutical industry is and will
remain the primary goal of 4SC AG and a major lever for increasing the
company value. With the planned capital increase, 4SC AG will not only
further develop the existing project pipeline, but also add other projects
that provide additional potential for added value and that will further
diversify the risk in the project portfolio to the development pipeline.
4SC AG's lead compound SC12267, which is currently in the clinical phase
IIa study, is progressing according to schedule. The results are
anticipated for the fourth quarter of 2007. Moreover, the drug candidates
SC68896 against haematopoietic and solid tumours and SC71570 from the
NFB project against chronic inflammatory bowel diseases are
currently undergoing advanced pre-clinical studies and will shortly be
ready for clinical studies. The proceeds from the capital measure will help
to exploit the potential of the company's own pipeline even better.
About 4SC:
4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of
Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now
with a staff of 61, the company develops novel drug candidates for
inflammatory diseases and cancer using a cheminformatics based technology
platform. Traditional high throughput screening of therapeutic agents has
been transferred from the lab to the computer. Thus, the company offers
substantial cost and time advantages as well as increased success rates in
drug development. 4SC AG uses its patented technology platform to create a
sustainable product pipeline for active agents that are developed in early
clinical phases ('proof of concept') and subsequently result in upfront and
milestone payments as well as participation in sales generated by
out-licensed products to the pharmaceutical industry. There are currently
six projects in the pipeline. The first project on the treatment of
rheumatoid arthritis is currently undergoing clinical phase IIa. Four other
product candidates are in preclinical development and another project is in
the research stage. Furthermore, the company has its technology platform in
co-operation projects with biotech and pharma companies and is already
generating initial revenues.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
Bettina von Klitzing
Manager Investor Relations und Public Relations
4SC AG
Phone: +49 (0) 89 70 07 63 - 0
[email protected]
On behalf of 4SC AG:
Sibylle Greiser
komm.passion Schumacher´s AG
Phone: +49 (0) 89 48 92 72 - 21
[email protected]
07.09.2007 Financial News transmitted by DGAP
Language: English
Issuer: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: [email protected]
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Indices:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service